Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

New TAVR Devices: Better Results in Bicuspids

Courtesy of del Dr. Carlos Fava.

 

sapien_xt_sapien_3 TAVR devicesThe bicuspid aortic valve is highly anatomically challenging because of valve asymmetric calcification, increased annulus diameter, raphe calcification and ascending aorta dilation. The new valves have shown to improve results, but we still lack data on this group.

 

301 patients presenting bicuspid aortic valve undergoing transcatheter aortic valve replacement (TAVR) were analyzed. 199 of these patients receive a first generation valve (FG) (Sapien XT: 87 y CoreValve: 112) and 102 a new generation valve (NG) (Sapien 3: 91 y Lotus: 11).

 

Populations were similar, except for ejection fraction, which resulted lower in those receiving NG (52.9% vs. 47.5%; p=0.004).

 

Device success rate was higher in those receiving NG:

NG: 92.2%

FG: 80.9%

[p=0.01]

 

Mild or severe paravalvular leak was also lower with NG:

NG: 0%

FG: 8.5%

[p=0.002]

 

There were no differences in:

  • Stroke
  • Life threatening bleeding
  • Major vascular complications
  • Kidney function deterioration
  • Safety end points
  • Cardiovascular or all-cause mortality in both groups at 30 days and one year (4.3% and 14.1%).

 

At multivariable analyzis, EuroSCORE ≥20, major bleeding and kidney function deterioration was associated to mortality (stages 2 or 3).

 

Conclusion

TAVR evolution in patients with bicuspid valve disease is favorable. New generation devices are associated with less paravalvular leak and higher device success.

 

Editorial Comment

This is the largest series to compare new generation devices against prior devices in this complex scenario to show they are beneficial in terms of device success and absence of paravalvular leak, with no differences in the rest of end points at one year.

 

Surely, at longer follow up, the presence of mild or severe paravalvular leak would translate into death.

 

Original Title: Transcatheter Aortic Valve Replacement with Early-and New-Generation Devices in Bicuspid Aortic valve Stenosis.

Reference: Sung-Han Yoon et al. J Am Coll Cardiol 2016;68:1195-205.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

We value your opinion. You are more than welcome to leave your comments, questions or suggestions here below.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...